Here’s why even bullish analyst Ram Selvaraju of H.C.
Synergy Pharmaceuticals (NASDAQ:SGYP) investors eagerly anticipating news regarding the company’s progress in commercializing its lead drug, Trulance, an FDA-approved treatment for chronic idiopathic …
Oppenheimer’s Christopher Liu thinks the Street is too confident on SGYP ahead of its first earnings show of the year- opting for now to stick to the sidelines.
H.C.
There’s a new FDA-approved IBS-C medication on the scene. Today, the U.
Wednesday could mark a turning point for Synergy investors.
Nagging capital overhang moves us to sidelines, says Derek Archila.
Shares in innovative biopharma Synergy Pharmaceuticals Inc (NASDAQ:SGYP) are rising 3% to $2.06 in today’s trading on the news that the company has …
How does Hedge fund guru Dmitry Balyasny’s choice to invest new stakes in Teva Pharmaceutical (NYSE:TEVA) and Synergy Pharmaceuticals (NASDAQ:SGYP) while bumping up …
Shares of biopharma Synergy Pharmaceuticals (NASDAQ:SGYP) are now almost half the price one month ago following a controversial equity offering. With prices so …
